Colby Suire, PhD joined Talaris Therapeutics as the Head of Research in 2021. Colby received a PhD from The University of Texas MD Anderson Cancer Center and has spent the next 9+ years in biotech during which he led research, process and analytical development projects to support early and late-stage clinical cell and gene therapy product candidates. Prior to joining Talaris, Colby was the Head of Analytical Development at Neurogene were he led analytical method development and qualification as well as directed technology transfer and method validation activities with external partners. Prior to joining Neurogene, Colby served in leadership positions as the Director of Process and Analytical Development for Medeor Therapeutics, Manager of Research for Cell Medica and Director of Research and Development at Mesoblast, Inc where he advanced pre-clinical and clinical products. In these roles, Mr. Suire contributed to several innovative discoveries as an inventor for IP and regulatory filings.
In his current role with Talaris, Colby leads pre-clinical development and exploratory clinical studies leveraging advanced technologies and single cell multiomic platforms. In addition, Mr. Suire leads our discovery efforts across a variety of research functions with multiple external partners.